Oral contraceptives as risk factors for cervical adenocarcinomas and squamous cell carcinomas

James V. Lacey, Louise A. Brinton, Fouad Abbas, Willard A. Barnes, Patti E. Gravitt, Mitchell D. Greenberg, Sarah M. Greene, Olympia C. Hadjimichael, Larry McGowan, Rodrigue Mortel, Peter E. Schwartz, Steven G. Silverberg, Allan Hildesheim

Research output: Contribution to journalArticle

Abstract

To assess the hypothesis that oral contraceptives (OCs) increase the risk of cervical adenocarcinomas, we conducted a six-center case-control study of 124 patients with adenocarcinomas, 139 with squamous cell carcinomas, and 307 population controls. Women between the ages of 18 and 69 who were newly diagnosed with cervical adenocarcinomas between 1992 and 1996 were eligible. Healthy female controls and a second case group of incident cervical squamous cell carcinomas were matched to the adenocarcinoma cases. All participants were interviewed regarding OCs, other risk factors for cervical carcinoma, and utilization of cytological screening, and a PCR-based test determined HPV genotype of cervical samples for both case groups and controls. Use of OCs was positively and significantly associated with adenocarcinomas and positively but weakly associated with squamous cell carcinomas. Associations between OCs and invasive adenocarcinomas (n = 91), squamous cell carcinoma in situ (n = 48), and invasive squamous cell carcinomas (n = 91) disappeared after accounting for HPV infection, sexual history, and cytological screening, but a positive association remained between current use of OCs and cervical adenocarcinoma in situ (n = 33). This association persisted after stratification by screening and sexual history and after restriction according to HPV status, but small numbers made it difficult to exclude detection bias, selection bias, or residual confounding by HPV as potential explanations. Current OC use was associated with cervical adenocarcinomas in situ, but we saw no other evidence that OCs independently increase the risk of cervical carcinomas.

Original languageEnglish (US)
Pages (from-to)1079-1085
Number of pages7
JournalCancer Epidemiology Biomarkers and Prevention
Volume8
Issue number12
StatePublished - Dec 1999

Fingerprint

Oral Contraceptives
Squamous Cell Carcinoma
Adenocarcinoma
Carcinoma
Population Control
Selection Bias
Carcinoma in Situ
Case-Control Studies
Genotype
Polymerase Chain Reaction
Control Groups
Infection

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Lacey, J. V., Brinton, L. A., Abbas, F., Barnes, W. A., Gravitt, P. E., Greenberg, M. D., ... Hildesheim, A. (1999). Oral contraceptives as risk factors for cervical adenocarcinomas and squamous cell carcinomas. Cancer Epidemiology Biomarkers and Prevention, 8(12), 1079-1085.

Oral contraceptives as risk factors for cervical adenocarcinomas and squamous cell carcinomas. / Lacey, James V.; Brinton, Louise A.; Abbas, Fouad; Barnes, Willard A.; Gravitt, Patti E.; Greenberg, Mitchell D.; Greene, Sarah M.; Hadjimichael, Olympia C.; McGowan, Larry; Mortel, Rodrigue; Schwartz, Peter E.; Silverberg, Steven G.; Hildesheim, Allan.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 8, No. 12, 12.1999, p. 1079-1085.

Research output: Contribution to journalArticle

Lacey, JV, Brinton, LA, Abbas, F, Barnes, WA, Gravitt, PE, Greenberg, MD, Greene, SM, Hadjimichael, OC, McGowan, L, Mortel, R, Schwartz, PE, Silverberg, SG & Hildesheim, A 1999, 'Oral contraceptives as risk factors for cervical adenocarcinomas and squamous cell carcinomas', Cancer Epidemiology Biomarkers and Prevention, vol. 8, no. 12, pp. 1079-1085.
Lacey JV, Brinton LA, Abbas F, Barnes WA, Gravitt PE, Greenberg MD et al. Oral contraceptives as risk factors for cervical adenocarcinomas and squamous cell carcinomas. Cancer Epidemiology Biomarkers and Prevention. 1999 Dec;8(12):1079-1085.
Lacey, James V. ; Brinton, Louise A. ; Abbas, Fouad ; Barnes, Willard A. ; Gravitt, Patti E. ; Greenberg, Mitchell D. ; Greene, Sarah M. ; Hadjimichael, Olympia C. ; McGowan, Larry ; Mortel, Rodrigue ; Schwartz, Peter E. ; Silverberg, Steven G. ; Hildesheim, Allan. / Oral contraceptives as risk factors for cervical adenocarcinomas and squamous cell carcinomas. In: Cancer Epidemiology Biomarkers and Prevention. 1999 ; Vol. 8, No. 12. pp. 1079-1085.
@article{4ca1bf4358574561aa01b62981af3f9d,
title = "Oral contraceptives as risk factors for cervical adenocarcinomas and squamous cell carcinomas",
abstract = "To assess the hypothesis that oral contraceptives (OCs) increase the risk of cervical adenocarcinomas, we conducted a six-center case-control study of 124 patients with adenocarcinomas, 139 with squamous cell carcinomas, and 307 population controls. Women between the ages of 18 and 69 who were newly diagnosed with cervical adenocarcinomas between 1992 and 1996 were eligible. Healthy female controls and a second case group of incident cervical squamous cell carcinomas were matched to the adenocarcinoma cases. All participants were interviewed regarding OCs, other risk factors for cervical carcinoma, and utilization of cytological screening, and a PCR-based test determined HPV genotype of cervical samples for both case groups and controls. Use of OCs was positively and significantly associated with adenocarcinomas and positively but weakly associated with squamous cell carcinomas. Associations between OCs and invasive adenocarcinomas (n = 91), squamous cell carcinoma in situ (n = 48), and invasive squamous cell carcinomas (n = 91) disappeared after accounting for HPV infection, sexual history, and cytological screening, but a positive association remained between current use of OCs and cervical adenocarcinoma in situ (n = 33). This association persisted after stratification by screening and sexual history and after restriction according to HPV status, but small numbers made it difficult to exclude detection bias, selection bias, or residual confounding by HPV as potential explanations. Current OC use was associated with cervical adenocarcinomas in situ, but we saw no other evidence that OCs independently increase the risk of cervical carcinomas.",
author = "Lacey, {James V.} and Brinton, {Louise A.} and Fouad Abbas and Barnes, {Willard A.} and Gravitt, {Patti E.} and Greenberg, {Mitchell D.} and Greene, {Sarah M.} and Hadjimichael, {Olympia C.} and Larry McGowan and Rodrigue Mortel and Schwartz, {Peter E.} and Silverberg, {Steven G.} and Allan Hildesheim",
year = "1999",
month = "12",
language = "English (US)",
volume = "8",
pages = "1079--1085",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Oral contraceptives as risk factors for cervical adenocarcinomas and squamous cell carcinomas

AU - Lacey, James V.

AU - Brinton, Louise A.

AU - Abbas, Fouad

AU - Barnes, Willard A.

AU - Gravitt, Patti E.

AU - Greenberg, Mitchell D.

AU - Greene, Sarah M.

AU - Hadjimichael, Olympia C.

AU - McGowan, Larry

AU - Mortel, Rodrigue

AU - Schwartz, Peter E.

AU - Silverberg, Steven G.

AU - Hildesheim, Allan

PY - 1999/12

Y1 - 1999/12

N2 - To assess the hypothesis that oral contraceptives (OCs) increase the risk of cervical adenocarcinomas, we conducted a six-center case-control study of 124 patients with adenocarcinomas, 139 with squamous cell carcinomas, and 307 population controls. Women between the ages of 18 and 69 who were newly diagnosed with cervical adenocarcinomas between 1992 and 1996 were eligible. Healthy female controls and a second case group of incident cervical squamous cell carcinomas were matched to the adenocarcinoma cases. All participants were interviewed regarding OCs, other risk factors for cervical carcinoma, and utilization of cytological screening, and a PCR-based test determined HPV genotype of cervical samples for both case groups and controls. Use of OCs was positively and significantly associated with adenocarcinomas and positively but weakly associated with squamous cell carcinomas. Associations between OCs and invasive adenocarcinomas (n = 91), squamous cell carcinoma in situ (n = 48), and invasive squamous cell carcinomas (n = 91) disappeared after accounting for HPV infection, sexual history, and cytological screening, but a positive association remained between current use of OCs and cervical adenocarcinoma in situ (n = 33). This association persisted after stratification by screening and sexual history and after restriction according to HPV status, but small numbers made it difficult to exclude detection bias, selection bias, or residual confounding by HPV as potential explanations. Current OC use was associated with cervical adenocarcinomas in situ, but we saw no other evidence that OCs independently increase the risk of cervical carcinomas.

AB - To assess the hypothesis that oral contraceptives (OCs) increase the risk of cervical adenocarcinomas, we conducted a six-center case-control study of 124 patients with adenocarcinomas, 139 with squamous cell carcinomas, and 307 population controls. Women between the ages of 18 and 69 who were newly diagnosed with cervical adenocarcinomas between 1992 and 1996 were eligible. Healthy female controls and a second case group of incident cervical squamous cell carcinomas were matched to the adenocarcinoma cases. All participants were interviewed regarding OCs, other risk factors for cervical carcinoma, and utilization of cytological screening, and a PCR-based test determined HPV genotype of cervical samples for both case groups and controls. Use of OCs was positively and significantly associated with adenocarcinomas and positively but weakly associated with squamous cell carcinomas. Associations between OCs and invasive adenocarcinomas (n = 91), squamous cell carcinoma in situ (n = 48), and invasive squamous cell carcinomas (n = 91) disappeared after accounting for HPV infection, sexual history, and cytological screening, but a positive association remained between current use of OCs and cervical adenocarcinoma in situ (n = 33). This association persisted after stratification by screening and sexual history and after restriction according to HPV status, but small numbers made it difficult to exclude detection bias, selection bias, or residual confounding by HPV as potential explanations. Current OC use was associated with cervical adenocarcinomas in situ, but we saw no other evidence that OCs independently increase the risk of cervical carcinomas.

UR - http://www.scopus.com/inward/record.url?scp=0033452120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033452120&partnerID=8YFLogxK

M3 - Article

C2 - 10613340

AN - SCOPUS:0033452120

VL - 8

SP - 1079

EP - 1085

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 12

ER -